SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-001018
Filing Date
2022-04-26
Accepted
2022-04-26 16:05:48
Documents
50
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20220331x10q.htm   iXBRL 10-Q 557157
2 EX-10.2 enzn-20220331xex10d2.htm EX-10.2 91449
3 EX-31.1 enzn-20220331xex31d1.htm EX-31.1 15290
4 EX-32.1 enzn-20220331xex32d1.htm EX-32.1 7126
  Complete submission text file 0001410578-22-001018.txt   2673912

Data Files

Seq Description Document Type Size
5 EX-101.SCH enzn-20220331.xsd EX-101.SCH 30941
6 EX-101.CAL enzn-20220331_cal.xml EX-101.CAL 15702
7 EX-101.DEF enzn-20220331_def.xml EX-101.DEF 91836
8 EX-101.LAB enzn-20220331_lab.xml EX-101.LAB 178506
9 EX-101.PRE enzn-20220331_pre.xml EX-101.PRE 160844
44 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20220331x10q_htm.xml XML 244154
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

IRS No.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 22854320
SIC: 2836 Biological Products, (No Diagnostic Substances)